Somewhat Positive News Coverage Somewhat Unlikely to Affect Spero Therapeutics (NASDAQ:SPRO) Share Price

News headlines about Spero Therapeutics (NASDAQ:SPRO) have trended somewhat positive recently, Accern reports. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Spero Therapeutics earned a daily sentiment score of 0.04 on Accern’s scale. Accern also gave news coverage about the company an impact score of 44.8421531133247 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the news articles that may have impacted Accern’s rankings:

How to Become a New Pot Stock Millionaire

NASDAQ:SPRO opened at $14.25 on Friday. Spero Therapeutics has a 12 month low of $9.66 and a 12 month high of $15.40.

SPRO has been the topic of several recent analyst reports. Oppenheimer set a $30.00 target price on shares of Spero Therapeutics and gave the stock a “buy” rating in a research report on Monday, December 11th. Zacks Investment Research raised shares of Spero Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a research report on Tuesday, January 30th. ValuEngine raised shares of Spero Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Finally, Cantor Fitzgerald initiated coverage on shares of Spero Therapeutics in a research report on Thursday, February 8th. They set an “overweight” rating and a $27.00 target price on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $24.25.

TRADEMARK VIOLATION WARNING: This piece of content was first published by BBNS and is the sole property of of BBNS. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://baseballnewssource.com/2018/03/30/spero-therapeutics-spro-receives-daily-coverage-optimism-rating-of-0-04/1973817.html.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections.

Insider Buying and Selling by Quarter for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Xander Bogaerts Goes on Red Sox DL
Xander Bogaerts Goes on Red Sox DL
Ohtani Goes Deep in Third Straight Game for Angels
Ohtani Goes Deep in Third Straight Game for Angels


Leave a Reply

 
© 2006-2018 BBNS.